QUINCE THERAPEUTICS INC (QNCX)
US22053A1079 - Common Stock
We assign a fundamental rating of 2 out of 10 to QNCX. QNCX was compared to 561 industry peers in the Biotechnology industry. QNCX may be in some trouble as it scores bad on both profitability and health. QNCX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year QNCX has reported negative net income.
In the past year QNCX has reported a negative cash flow from operations.
QNCX had negative earnings in each of the past 5 years.
In the past 5 years QNCX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -42.10%, QNCX perfoms like the industry average, outperforming 54.41% of the companies in the same industry.
QNCX has a Return On Equity of -118.54%. This is comparable to the rest of the industry: QNCX outperforms 40.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.1% | ||
| ROE | -118.54% | ||
| ROIC | N/A |
ROA(3y)-45.31%
ROA(5y)-41.24%
ROE(3y)-54.69%
ROE(5y)-48.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
QNCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for QNCX has been increased compared to 1 year ago.
QNCX has more shares outstanding than it did 5 years ago.
QNCX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.95, we must say that QNCX is in the distress zone and has some risk of bankruptcy.
QNCX has a Altman-Z score (-3.95) which is in line with its industry peers.
A Debt/Equity ratio of 0.33 indicates that QNCX is not too dependend on debt financing.
The Debt to Equity ratio of QNCX (0.33) is worse than 71.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.95 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
QNCX has a Current Ratio of 9.53. This indicates that QNCX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of QNCX (9.53) is better than 79.46% of its industry peers.
A Quick Ratio of 9.53 indicates that QNCX has no problem at all paying its short term obligations.
The Quick ratio of QNCX (9.53) is better than 79.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.53 | ||
| Quick Ratio | 9.53 |
3. Growth
3.1 Past
The earnings per share for QNCX have decreased strongly by -59.76% in the last year.
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, QNCX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.3%
EPS Next 2Y34.19%
EPS Next 3Y21.66%
EPS Next 5Y19.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for QNCX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
QNCX's earnings are expected to grow with 21.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.19%
EPS Next 3Y21.66%
5. Dividend
5.1 Amount
No dividends for QNCX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUINCE THERAPEUTICS INC
NASDAQ:QNCX (1/6/2025, 5:20:01 PM)
After market: 2 +0.01 (+0.5%)1.99
+0.04 (+2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.27%
Inst Owner ChangeN/A
Ins Owners13.29%
Ins Owner Change6.54%
Market Cap87.56M
Analysts82.22
Price Target9.18 (361.31%)
Short Float %6.3%
Short Ratio3.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-81.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.65%
EPS NY rev (3m)30.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS1.02
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.1% | ||
| ROE | -118.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-45.31%
ROA(5y)-41.24%
ROE(3y)-54.69%
ROE(5y)-48.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.51% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.53 | ||
| Quick Ratio | 9.53 | ||
| Altman-Z | -3.95 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.88%
Cap/Depr(5y)42.87%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y60.3%
EPS Next 2Y34.19%
EPS Next 3Y21.66%
EPS Next 5Y19.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.14%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.16%
OCF growth 3YN/A
OCF growth 5YN/A